Evaluation of Data Entry Errors and Data Changes to an Electronic Data Capture Clinical Trial Database

被引:33
作者
Mitchel, Jules T. [1 ]
Kim, Yong Joong [1 ,2 ]
Choi, Joonhyuk [1 ]
Park, Glen [3 ]
Cappi, Silvana [4 ]
Horn, David [5 ]
Kist, Morgan [6 ]
D'Agostino, Ralph B., Jr. [7 ]
机构
[1] Target Hlth Inc, Applicat Dev, New York, NY 10016 USA
[2] Target Hlth Inc, Data Management, New York, NY 10016 USA
[3] Target Hlth Inc, Clin & Regulatory Affairs, New York, NY 10016 USA
[4] Ferring Int PharmaSci Ctr, Copenhagen, Denmark
[5] Energetics Inc, Washington, DC USA
[6] Haverford Coll, Philadelphia, PA USA
[7] Wake Forest Univ, Sch Med, Ctr Comprehens Canc, Winston Salem, NC 27109 USA
来源
DRUG INFORMATION JOURNAL | 2011年 / 45卷 / 04期
关键词
EDC; Data management; Risk-based monitoring;
D O I
10.1177/009286151104500404
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Monitoring of clinical trials includes several disciplines, stakeholders, and skill sets. The aim of the present study was to identify database changes and data entry errors to an electronic data capture (EDC) clinical trial database, and to assess the impact of the changes. To accomplish the aim. Target e*CRF was used as the EDC tool for a multinational, dose-finding, multicenter, double-blind, randomized, parallel, placebo-controlled trial to investigate efficacy and safety of a new treatment in men with lower urinary tract symptoms associated with benign prostatic hyperplasia. The main errors observed were simple transcription errors from the paper source documents to the EDC database. This observation was to be expected, since every transaction has an inherent error rate. What and how to monitor must be assessed within the risk-based monitoring section of the comprehensive data monitoring plan. With the advent of direct data entry, and the elimination of the requirement to transcribe from a paper source record to an EDC system, error rates should go down dramatically. In addition, protocol violations and data outside the normal range can be identified at the time of data entry and not days, weeks, and months after the fact.
引用
收藏
页码:421 / 430
页数:10
相关论文
共 11 条
[1]  
[Anonymous], ICH TOP E9 STAT PRIN
[2]   Developing systems for cost-effective auditing of clinical trials [J].
Califf, RM ;
Karnash, SL ;
Woodlief, LH .
CONTROLLED CLINICAL TRIALS, 1997, 18 (06) :651-660
[3]   Reducing the costs of phase III cardiovascular clinical trials [J].
Eisenstein, EL ;
Lemons, PW ;
Tardiff, BE ;
Schulman, KA ;
Jolly, MK ;
Califf, RM .
AMERICAN HEART JOURNAL, 2005, 149 (03) :482-488
[4]   Sensible approaches for reducing clinical trial costs [J].
Eisenstein, Eric L. ;
Collins, Rory ;
Cracknell, Beena S. ;
Podesta, Oscar ;
Reid, Elizabeth D. ;
Sandercock, Peter ;
Shakhov, Yuriy ;
Terrin, Michael L. ;
Sellers, Mary Ann ;
Califf, Robert M. ;
Granger, Christopher B. ;
Diaz, Rafael .
CLINICAL TRIALS, 2008, 5 (01) :75-84
[5]  
Food and Drug Administration, 1998, GUID IND PROV CLIN E
[6]  
*FOOD DRUG ADM, 2007, HSP BIMO WORKSH 5 10
[7]  
Helms RW, 2001, DRUG INF J, V35, P827, DOI 10.1177/009286150103500320
[8]  
Khosla R., 2000, Indian Journal of Pharmacology, V32, P180
[9]  
MITCHEL JT, 2010, APPL CLIN TRIALS MAY
[10]  
*SOC CLIN DAT MAN, 2010, GOOD CLIN DAT MAN PR